0001493152-23-036581.txt : 20231006
0001493152-23-036581.hdr.sgml : 20231006
20231006184355
ACCESSION NUMBER: 0001493152-23-036581
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231004
FILED AS OF DATE: 20231006
DATE AS OF CHANGE: 20231006
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sakiris Spiro Kevin
CENTRAL INDEX KEY: 0001830957
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39825
FILM NUMBER: 231315190
MAIL ADDRESS:
STREET 1: 708 THIRD AVENUE, 6TH FLOOR
CITY: NEW YORK CITY
STATE: NY
ZIP: 10017
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: INTELLIGENT BIO SOLUTIONS INC.
CENTRAL INDEX KEY: 0001725430
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 821512711
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 142 WEST 57TH ST FL11
CITY: NEW YORK
STATE: NY
ZIP: 10019
BUSINESS PHONE: 646-233-6971
MAIL ADDRESS:
STREET 1: 142 WEST 57TH ST FL11
CITY: NEW YORK
STATE: NY
ZIP: 10019
FORMER COMPANY:
FORMER CONFORMED NAME: GBS Inc.
DATE OF NAME CHANGE: 20190919
FORMER COMPANY:
FORMER CONFORMED NAME: Glucose Biosensor Systems (Greater China) Holdings, Inc.
DATE OF NAME CHANGE: 20171214
4
1
ownership.xml
X0508
4
2023-10-04
0
0001725430
INTELLIGENT BIO SOLUTIONS INC.
INBS
0001830957
Sakiris Spiro Kevin
C/O INTELLIGENT BIO SOLUTIONS INC.,
142 WEST 57TH STREET, 11TH FLOOR
NEW YORK
NY
10019
0
1
0
0
Chief Financial Officer
0
Common Stock
3765
D
Common Stock
2023-10-04
4
P
0
112727
A
117427
I
Held by Anest Holdings Pty Ltd
Common Stock Warrants (Series E)
2023-10-04
4
P
0
112727
A
2029-04-04
Common Stock
112727
112727
I
Held by Anest Holdings Pty Ltd
Common Stock Warrants (Series F)
2023-10-04
4
P
0
112727
A
2025-04-04
Common Stock
112727
112727
I
Held by Anest Holdings Pty Ltd
The reported securities are included within 112,727 INBS Class A Units purchased by the reporting person for $0.55 per Unit. Each Unit consists of one share of the common stock, one warrant to purchase one share of Common Stock at an exercise price of $0.55 per share ("Series E Warrants"), and one warrant to purchase one share of Common Stock at an exercise price of $0.55 per share ("Series F Warrants"). The Warrants will be exercisable beginning on the effective date of such stockholder approvals as may be required by the applicable rules and regulations of the Nasdaq Capital Market (or any successor entity) to permit the exercise of the Warrants ("Warrant Stockholder Approval").
The exercise price of the Series E Warrants is $0.55 per share. However, under the one-time reset provision of the Series E Warrants, the exercise price of the Series E Warrants will reset to a price equal to the lesser of (i) the then exercise price and (ii) 90% of the five-day volume weighted average price for the five trading days immediately following the date the Company effects a reverse stock split.
The exercise price of the Series F Warrants is $0.55 per share. However,under the alternate cashless exercise option of the Series F Warrants, the holder of the Series F Warrant (beginning on the date the Warrant Stockholder Approval is effective), has the right to receive an aggregate number of shares of Common Stock on a one-for-one basis (subject to adjustment).
These securities are held by Anest Holdings Pty Ltd, as trustee of ATF S&T Sakiris Superannuation Fund, of which Mr. Sakiris is a director.
/s/ Spiro Sakiris
2023-10-06